Weekly Analysts’ Ratings Changes for Regeneron Pharmaceuticals (REGN)

Several analysts have recently updated their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

• 12/15/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/12/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $767.00 to $768.00. They now have an “equal weight” rating on the stock.
• 12/10/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $700.00 to $745.00. They now have an “equal weight” rating on the stock.
• 12/8/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Canaccord Genuity Group Inc. from $850.00 to $1,057.00. They now have a “buy” rating on the stock.
• 12/4/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $725.00 to $850.00. They now have an “outperform” rating on the stock.
• 12/3/2025 – Regeneron Pharmaceuticals was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $767.00 price target on the stock.
• 12/1/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Regeneron Pharmaceuticals was upgraded by analysts at Hsbc Global Res to a “strong-buy” rating.
• 11/24/2025 – Regeneron Pharmaceuticals is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $798.00 price target on the stock.
• 11/24/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Scotiabank from $650.00 to $770.00. They now have a “sector perform” rating on the stock.
• 11/24/2025 – Regeneron Pharmaceuticals is now covered by analysts at HSBC Holdings plc. They set a “buy” rating and a $255.00 price target on the stock.
• 11/20/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $615.00 to $700.00. They now have an “equal weight” rating on the stock.
• 11/18/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Regeneron Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/13/2025 – Regeneron Pharmaceuticals is now covered by analysts at Scotiabank. They set a “sector perform” rating and a $650.00 price target on the stock.
• 11/12/2025 – Regeneron Pharmaceuticals was upgraded by analysts at Scotiabank to a “hold” rating.
• 11/9/2025 – Regeneron Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/7/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at UBS Group AG from $595.00 to $660.00. They now have a “neutral” rating on the stock.
• 11/1/2025 – Regeneron Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Citigroup Inc. from $660.00 to $700.00. They now have a “buy” rating on the stock.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $704.00 to $708.00. They now have a “sector perform” rating on the stock.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $580.00 to $615.00. They now have an “equal weight” rating on the stock.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Cantor Fitzgerald from $678.00 to $740.00. They now have an “overweight” rating on the stock.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Guggenheim from $815.00 to $865.00. They now have a “buy” rating on the stock.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $543.00 to $627.00. They now have an “underperform” rating on the stock.
• 10/23/2025 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $850.00 price target on the stock.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Insider Buying and Selling

In related news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.